PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

Introduction: HER2-enriched subtype has been associated with higher response to neoadjuvant anti-HER2-based therapy across various clinical trials. However, limited data exist in real-world practice and regarding residual disease. Here, we evaluate the association of HER2-enriched with pathological...

Descripción completa

Detalles Bibliográficos
Autores principales: Pernas, Sonia, Petit, Anna, Climent, Fina, Paré, Laia, Perez-Martin, J., Ventura, Luz, Bergamino, Milana, Galván, Patricia, Falo, Catalina, Morilla, Idoia, Fernandez-Ortega, Adela, Stradella, Agostina, Rey, Montse, Garcia-Tejedor, Amparo, Gil-Gil, Miguel, Prat, Aleix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691353/
https://www.ncbi.nlm.nih.gov/pubmed/31448227
http://dx.doi.org/10.3389/fonc.2019.00707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691353/
https://www.ncbi.nlm.nih.gov/pubmed/31448227
http://dx.doi.org/10.3389/fonc.2019.00707

Ejemplares similares